The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, ...
This follows a similar move the FTC made in November involving 100 patents filed by pharma companies. The latest spate of “junk patent” listings include medicines for diabetes, asthma, COPD, and ...
disputing the accuracy of some 300 patent listings in the Food and Drug Administration’s so-called “Orange Book.” The crackdown, which comes six months after FTC challenged 10 pharma majors in a ...
The FTC’s recent action extends beyond Novo Nordisk, with warning letters sent to multiple pharmaceutical companies challenging the accuracy or relevance of over 300 patent listings across various ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for anticompetitive use of so-called junk ...